Eugene

[email protected]

LATEST

New Cell and Gene Therapy CDMO Launches with $1.1-Bn Investment
By

By
The Discovery Labs, a provider of cGMP manufacturing, turnkey laboratory solutions, materials and office space for building life-sciences and technology companies, and Deerfield Management Company, an investment firm, have launched…

AstraZeneca To Invest $1 Bn to Accelerate Sustainability Projects
By

By
AstraZeneca plans to invest $1 billion under a strategy to achieve zero-carbon emissions from its global operations by 2025 and to ensure its entire value chain is carbon-negative by 2030.…

Piramal To Divest Healthcare Analytics Unit for $950 Million
By

By
Piramal has agreed to sell its healthcare data and analytics unit, Decision Resources Group (DRG), to Clarivate Analytics for $950 million (includes $900 million on closing and $50 million to…

Merck & Co. Completes $2.7-Bn Acquisition of ArQule
By

By
Merck & Co. has completed its previously announced $2.7-billion acquisition of ArQule, a biopharmaceutical company focused on the discovery and development of kinase inhibitors for treating cancer and other diseases.…

Lilly To Invest $470 M in New Parenteral Mfg Facility in North Carolina
By

By
Eli Lilly and Company reports that it will invest more than $470 million to build a new parenteral (injectable) product and delivery device manufacturing facility in North Carolina’s Research Triangle Park. The new…

Civica Rx, Thermo Fisher Sign Long-Term Mfg Pact for Generics in Shortage
By

By
Civica Rx, a pharmaceutical company providing drugs in shortage, has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications of Civica-owned abbreviated new drug applications. This…

AstraZeneca To Invest More Than $500 M into Mfg and Research in France
By

By
AstraZeneca is investing more than $500 million over five years in France in several manufacturing and research and development (R&D) projects, including a $230-million investment to expand its manufacturing site…

Astellas Completes $3-Bn Acquisition of Audentes Therapeutics
By

By
Astellas has completed its $3-billion acquisition of Audentes Therapeutics, a San Francisco, California-based adeno-associated virus (AAV) clinical-stage gene-therapy company that focuses on rare neuromuscular diseases. With the completion of the…

AbbVie To Create New Global Aesthetics Business
By

By
AbbVie, upon completing its $63-billion acquisition of Allergan, plans to create a new global business, Allergan Aesthetics, which will include Allergan’s Botox and related products. The new business will become…

Biogen To Acquire Clinical-Stage CNS Asset from Pfizer in $710-M Deal
By

By
Biogen has agreed to acquire from Pfizer a clinical-stage small-molecule drug for treating neurological diseases in a deal worth up to $710 million ($75 million upfront and $635 million in…